



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2021-2022

LFIR # 2064

1. Project Title

Pilot Project - Opioid addiction prevention through objective risk assessment

2. Senate Sponsor

Darryl Rouson

3. Date of Request

03/16/2021

4. Project/Program Description

Every day in 2018, 130 Americans including 13 Floridians died from an opioid overdose. Since the COVID-19 pandemic began, more than 40 states have reported increases in opioid-related fatalities. Prescription opioids continue to be a source of new addiction with up to 10% of surgical patients still using opioids 12 months after surgery. Prevention tools such as risk assessment prior to prescribing are critical to address the problem. An objective, genetic risk assessment to determine an individual's risk of opioid addiction is now available for use by physicians and patients. When deploying this HIPAA compliant, clinically validated test, physicians can decrease/eliminate oral opioid use for high risk patients and avoid addiction. The funding requested will support a pilot project in Florida with 350 subjects to demonstrate the potential of this novel technology to reduce opioid prescriptions and opioid addiction across Florida.

5. State Agency to receive requested funds

Department of Health

State Agency contacted?

No

6. Amount of the Nonrecurring Request for Fiscal Year 2021-2022

Type of Funding	Amount
Operations	517,500
Fixed Capital Outlay	0
Total State Funds Requested	517,500

7. Total Project Cost for Fiscal Year 2021-2022 (including matching funds available for this project)

Type of Funding	Amount	Percentage
Total State Funds Requested (from question #6)	517,500	100%
Matching Funds		
Federal	0	0%
State (excluding the amount of this request)	0	0%
Local	0	0%
Other	0	0%
Total Project Costs for Fiscal Year 2021-2022	517,500	100%

8. Has this project previously received state funding?

No

Fiscal Year (yyyy-yy)	Amount		Specific Appropriation #	Vetoed
	Recurring	Nonrecurring		

9. Is future funding likely to be requested?

No

a. If yes, indicate nonrecurring amount per year.

b. Describe the source of funding that can be used in lieu of state funding.



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2021-2022

LFIR # 2064

10. Has the entity requesting this project received any federal assistance related to the COVID-19 pandemic?

Yes

If yes, indicate the amount of funds received and what the funds were used for.

SOLVD Health received \$1,542,000.00 in principal from the Paycheck Protection Program. These funds were used to fund employee salaries and other expenses per the guidelines of the program.
The principal amount of the loan of \$1,542,000.00 and \$10,237.17 in interest were forgiven on 12/9/2020.

11. Details on how the requested state funds will be expended

Spending Category	Description	Amount
Administrative Costs:		
Executive Director/Project Head Salary and Benefits		0
Other Salary and Benefits		0
Expense/Equipment/Travel/Supplies/Other	Travel to patient sites in Florida and other administrative expenses.	10,000
Consultants/Contracted Services/Study		0
Operational Costs: Other		
Salary and Benefits		0
Expense/Equipment/Travel/Supplies/Other	Laboratory testing (400 tests @ \$450 per test) Patient/subject compensation (300 patients/subjects @ \$50 per patient/subject)	157,500
Consultants/Contracted Services/Study	Contract Research Organization (CRO) to provide support for clinical study design and clinical site identification and management including the acquisition, tracking and analysis of patients in the demonstration project.	350,000
Fixed Capital Construction/Major Renovation:		
Construction/Renovation/Land/Planning Engineering		0
Total State Funds Requested (must equal total from question #6)		517,500

12. Program Performance

a. What specific purpose or goal will be achieved by the funds requested?

This study will determine the impact of the genetic risk assessment on the number and length of opioid prescriptions when physicians consider the results of the test prior to surgery to develop a post-operative pain management plan. A decision-impact analysis will be done to compare pain management plans provided to patients who did and did not receive the risk assessment including prescribing patterns and patient outcomes for patients with High Risk and Low Risk results. The study will also track patients for up to 12 months following surgery and the subsequent oral opioid exposure to evaluate the extent to which patients who receive the test will experience persistent opioid use (i.e. significantly longer use than otherwise expected for the type of surgery) and/or develop OUD as compared to patients who receive the current standard of care.

b. What activities and services will be provided to meet the intended purpose of these funds?

The funds for this study will support all aspects of a demonstration project. The activities include finalization of a clinical study design, identification and enrollment of clinical study sites, site onboarding/training, site management, patient acquisition, patient laboratory testing using the objective risk assessment, patient tracking, outcome tracking, data analysis and generation of a manuscript describing the project and results.

c. What direct services will be provided to citizens by the appropriation project?



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2021-2022

LFIR # 2064

Florida citizens taking part in the study will receive the objective risk assessment which they can use along with their physician to make informed decisions about the use of opioids for acute pain management including, but not limited to post-surgical pain management.
Note that because the test considers an individual's genetics, the results of the test for an individual do not change over time making the data useful to the patient and his/her physician(s) for their lifetime.

d. Who is the target population served by this project? How many individuals are expected to be served?

The target population will be patients receiving acute pain management care following an elective surgery; i.e. total knee replacement.
A total number of 350 individuals will be included in this study. Based on the results of the study and demonstrated success of the test to reduce opioid exposure and OUD, the risk assessment test could be deployed more broadly to a target population of all Floridians who receive oral opioids for acute pain (e.g. for between 4 and 30 days) including, but not limited to, patients receiving opioids following elective surgery.

e. What is the expected benefit or outcome of this project? What is the methodology by which this outcome will be measured?

The benefit of this project is to determine the potential impact of the objective risk assessment for OUD to effectively reduce the number and amount of opioids prescribed, opioid addiction and opioid related deaths in Florida . Based on the result of this study, the state of Florida can determine the potential value of making this test more widely available to its citizens in order to reduce the overall human and financial cost to the state.
The outcomes of this study will be measured using standard measurements typical for a scientific and medical study of this nature.

f. What are the suggested penalties that the contracting agency may consider in addition to its standard penalties for failing to meet deliverables or performance measures provided for the contract?

Revert funds

13. The owners of the facility to receive, directly or indirectly, any fixed capital outlay funding. Include the relationship between the owners of the facility and the entity.

N/A



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2021-2022

LFIR # 2064

14. Requestor Contact Information

a. First Name Last Name

b. Organization

c. E-mail Address

d. Phone Number Ext.

15. Recipient Contact Information

a. Organization

b. Municipality and County

c. Organization Type

- ☒ For Profit Entity
- ☐ Non Profit 501(c)(3)
- ☐ Non Profit 501(c)(4)
- ☐ Local Entity
- ☐ University or College
- ☐ Other (please specify)

d. First Name Last Name

e. E-mail Address

f. Phone Number

16. Lobbyist Contact Information

a. Name

b. Firm Name

c. E-mail Address

d. Phone Number